Universal multi-variant detection system

ABSTRACT

The present invention provides a method to diagnostically detect the variants of a given pathogen, such as HIV, hepatitis C, hepatitis B (HBV), Parvovirus B19, etc., with the use of a single detection probe.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application No.60/284,334, filed Apr. 17, 2001, which is incorporated herein byreference.

BACKGROUND OF THE INVENTION

The detection of closely related genetic variants is a significantchallenge of analytical diagnostics. Pathogens such as, for example,viruses and bacteria, generally mutate frequently and form such geneticvariants.

For example, the nucleic acid sequences of human immunodeficiency virus(HIV-1) having different origins, are different from each other. Thedifferent types of HIV-1 are divided into groups and subtypes. The majorgroup M consists of ten currently identified subtypes, designated assubtypes A through H, J and K In addition to M-group viruses, two othergroups, N and O, have been identified (Simon et al, 1998, Nature Med,4:1032-1037). Within groups and subtypes, new strains of the virus arecontinuously being generated due to the error-prone nature of the HIV-1replicative machinery.

Similarly, hepatitis C virus (HCV) does not exist as a homogeneous RNApopulation. Even within a single infected individual, numerousheterogeneous viral genomes (quasispecies) may co-exist. In addition,multiple genotypes of HCV have been identified on the basis ofnucleotide sequence analysis of viral variants isolated from differentgeographic regions. There are currently six main HCV genotypes,classified numerically from 1 to 6. Genotypes are further subdividedaccording to subtype.

Due to this genetic variation of pathogens within a species, the rangeof diagnostic tests that provide reliable results are highly limited.Most detection methods currently available for detecting pathogens in asample are based either on the detection of the pathogens' antigens,pathogen-induced antibodies, or the pathogens' intrinsic enzymes, e.g.intrinsic HIV reverse transcriptase. In addition to being inconvenient,such methods are frequently not very sensitive. For example, the methodcurrently implemented by blood banks for screening of HIV-1 infection inblood donors is the detection of antibodies to virus proteins. Thismethod fails to detect individuals in the early acute phase of theinfection who have not yet developed diagnostic antibodies to the virus.

Screening methods that are based on the detection of nucleic acidsequences are sensitive and convenient. However, these tests may notalways be reliable for detection of closely related genetic variants.

One of the currently available nucleic acid sequence-based detectionmethods utilizes molecular beacons (Tyagi and Kramer, 1996, Nat.Biotechnol., 14(3):303-308). Molecular beacons are single-strandedoligonucleotide probes that have a stem-loop structure. (See FIG. 1.)The loop portion of the molecule is a probe sequence complementary to atarget nucleic acid molecule. The stem is formed by the annealing ofcomplementary arm sequences on the ends of the probe sequence. Afluorescent moiety is attached to the end of one arm; and a quenchingmoiety is attached to the end of the other arm. The hybridization of thearms of the stem to each other keeps these two moieties in closeproximity, causing the fluorescence of the fluorophore to be quenched byenergy transfer (FIG. 1 a). In the presence of the beacon'scomplementary DNA target, the loop structure hybridizes to the target,preventing the arms of the stem from remaining hybridized. Thefluorophore and quencher are physically separated, and fluorescence isobtained (FIG. 1 b).

Molecular beacons are currently used for real-time quantitative PCR. PCRprimers are designed to amplify a specific segment of DNA, usually lessthan 200 base pairs in length. The beacon is typically designed so thatits loop is complementary to a short (20-25 b.p.) region on one of theamplified DNA strands. The complementary region of these amplified DNAstrands is the portion of these strands which has been added to theprimers.

Molecular beacons are highly sequence-specific. In fact, one of theprinciple applications of this technology in recent years has been forallele discrimination or “molecular genotyping.” The sensitivity ofmolecular beacons to sequence variation permits discrimination betweeneven single nucleotide polymorphisms in a give target sequence (Tyagi etal, 1998, Nat. Biotechnol., 16(1):49-53; Kostrikis et al., 1998,Science, 279:5354:1228-9; Marras et al., 1999, Genet. Anal.,14(5-6)151-6; Tapp et al., 2000, Biotechniques, 28(4):732-8).

To date, this sensitivity to sequence variation has severely limited theapplication of molecular beacon technology to the diagnosis of viralinfection. The molecular beacons cannot efficiently detect the variantsequences of DNA or RNA targets. For example, a beacon designed torecognize PCR product from HIV strain A may not recognize PCR productfrom HIV strain B. (See FIG. 2.)

Thus, the present technology would require several different beacons toallow for the detection of all the different genotypes of the virus.That is, even though some highly conserved regions of the genome ofHIV-1 are known to exist, it is likely that several different beaconswould be needed to detect all the known subtypes of this virus.Moreover, even with the use of several different beacons, other variantsof HIV-1 that have not been identified may not be detected.

Thus, current technology does not provide a convenient or efficientdiagnostic assay for detection of all related genetic variants ofpathogens.

There is an urgent need for sensitive, convenient nucleic acid-basedscreening assays capable of detecting closely related genetic variants.For example, there is a need for assays capable of detecting viruses,bacteria and other pathogens, directly in contaminated blood. Suchassays are needed to detect blood or plasma units from individuals inthe early acute stages of a pathogen infection, i.e., before theindividual has developed diagnostic antibodies to the virus.

Accordingly, one of the purposes of the present invention is to overcomethe above limitations in the prior art by providing a convenient andefficient diagnostic assay for detection of multiple variants of aparticular target nucleic acid molecule.

SUMMARY OF THE INVENTION

These and other objects, as will be apparent to those having ordinaryskill in the art, have been met by providing a method to diagnosticallydetect the variants of a given pathogen, such as HIV, hepatitis C,hepatitis B (HBV), Parvovirus B19, etc., with the use of a singledetection probe, i.e., a universal multi-variant detection system. Inone embodiment, the single detection probe is a molecular beacon.

BRIEF DESCRIPTION OF FIGURES

FIG. 1: A graphical illustration of a molecular beacon. At theappropriate annealing temperature the beacon will either: (A) in theabsence of a complementary target sequence, form a stem loop structurecausing the quenching moiety (□) to quench the luminescence of thereporter moiety (O); or (B) in the presence of a complementary target,bind to the target allowing the reporter to emit its signal.

FIG. 2: Conventional PCR using molecular beacons. PCR primers aredesigned to amplify a segment of viral RNA. A molecular beacon isdesigned so that its probe loop will hybridize to a segment of the PCRproduct which is internal to the two PCR primers. The beacon is capableof hybridizing to PCR product of virus strain A, but fails to detect PCRproduct of virus strain B because of mismatches in the target sequence(shown in lower case).

FIG. 3: A graphical illustration of one of the principles of theinvention. (a.) Reverse and forward PCR primers (>30 b.p.) are designedto hybridize directly “nose-to-nose” to the target RNA (or DNA) and itscomplementary DNA strand respectively, such that the generated PCRproduct possesses no intervening sequence. The target-specific loop ofthe molecular beacon is designed to hybridize to the DNA sequencecreated by the junction of one of the primers and the other primer'scomplement. PCR primers will hybridize to target templates withmismatched residues, indicated by “X.” Dotted lines indicatehybridization. (b.) The DNA sequence of the PCR product amplified fromall templates is identical to the combined sequence of one of theprimers and the other primer's complement. The molecular beacon is thuscapable of hybridizing to PCR products generated from all templates.

FIG. 4: An example of the method. An amplification of different subtypesof HIV using “nose-to-nose” primers and a molecular beacon designed torecognize a sequence created by the junction of one of the primers andthe other primer's complement. Mismatches between the sequence of theHIV variants and either the primers or beacon loop are shown in lowercase boldface.

FIG. 5: Illustration of Variations on Primer Location. (A). The beaconloop can be designed to hybridize to an amplified sequence createdequally by the two PCR primers as shown in (I). Alternatively, thebeacon can be designed to hybridize “asymmetrically” to an amplifiedsequence created primarily by either the forward or reverse primer asshown in (II) to (IV). (B). In a further variation, the forward andreverse primers are separated by a nucleotide gap which corresponds to ahighly conserved region of the viral genome.

FIG. 6: DNA sequence alignment of the V3 loop and flanking regions offour variants of HIV showing the positions of molecular beacon andprimers for both conventional and “nose-to-nose” PCR (a). The proteincoding strand of HIV/RT-1 is aligned with that of 3 other virusvariants, HIV/RT-10, HIV-38-1 and HIV/38-3. Mismatches to the sequenceof HIV/RT-1 and to the molecular beacon are shown in lower case in bold.The relative location of forward and reverse primers for conventionalPCR are indicated by dotted (. . . .) and dashed (- - - -) linesrespectively. The relative location of forward and reverse primers fornose-to-nose PCR are indicated by double (═) and solid (—) linesrespectively. The location of the beacon probe is shown above thesequence. All primers and the beacon probe sequences are derived fromthe sequence of HIV/RT-1. (b). Structure of the molecular beacon. Theprobe loop is shown in upper case, the complementary stem nucleotidesare shown in lower case. The fluorophore FAM is conjugated to the 5′end, the quencher DABCYL is conjugated to the 3′ end.

FIG. 7: Comparison of Conventional and Nose-to-Nose PCR Real TimeQuantitative PCR Methods. Real Time Quantitative PCR of four differentHIV variants using: (a) conventional or (b) “Nose-to-Nose” PCR methods.PCR reactions contained 10⁶ copies HIV/RT-1 (●), HIV/RT-10 (o), HIV/38-1(▾), HIV/38-3 (□), no template (+) or 150 ng Human DNA (x).

FIG. 8: Agarose Gel Analysis of Products Generated by Conventional PCR.Gel shows PCR products generated from HIV/RT-1, HIV/RT-10, HIV/38-1, andHIV/38-3 by the conventional PCR method. Lane 1: 50 bp ladder, Lane 2:No template, Lane 3: HIV/RT-1, Lane 4: HIV/RT-10, Lane 5: HIV/38-1, Lane6: HIV/38-3.

FIG. 9: An example of a standard curve for quantitation of HCV RNA using“nose-to-nose” RT-PCR with product detection using a molecular beacon.(a). “Nose-to-Nose” RT-PCR for HCV RNA was performed with an input of 0,10, 25, 50, 100, 10³, 10⁴, 10⁵ or 10⁶ synthetic HCV RNA molecules perRT-PCR reaction. Change in fluorescence (delta Rn) was measured at theannealing temperature for each PCR cycle in the ABI 7700 SequenceDetector. Threshold values (Ct) were then calculated using softwareprovided with the instrument. (b). The RNA copy number of each standardsample is plotted against its Ct value (●). The Ct values for unknowntest samples (o) are plotted against the standard curve and RNA copynumber is extrapolated from the X-axis.

FIG. 10: A step-by-step illustration of an amplification reaction of theinvention.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention provides a method for determining the presence ofa target nucleic acid molecule in a biological sample with the use of asingle detection probe.

The method comprises the amplification of a target nucleic acid moleculeby means of a primer extension chain reaction wherein the primers of thereaction are a set of “nose-to-nose” primers, including a forward andreverse primer, as described below. (See FIGS. 3 and 4.)

The target nucleic acid molecule is a nucleic acid molecule whose fullor partial sequence is sufficiently known to make primer extension chainreaction primers. The target nucleic acid molecule can be single ordouble stranded.

The target nucleic acid molecule exists as a family of highly homologoussequences. These different sequences within a family are referred to asvariants. The origin of the variants include, for example, genemutations and polymorphisms.

Nucleic acid molecules which are known to have variants include, forexample, viruses and bacteria. Examples of viruses include HIV, HCV, HBVand human parvovirus B19. Examples of bacteria include E. coli, S.pneumoniae, N. meningitidis, N. gonorrhoeae, M. Tuberculosis andBorrelia species (Lyme disease).

A biological sample from which a target nucleic acid molecule can bedetected is any bodily fluid, cells or cellular debris. Examples ofbiological samples include blood, serum, semen, mucous or other bodilyexudates.

The present invention can be used in any type of primer extension chainreaction that leads to the amplification of the target nucleic acidmolecule or a subregion of this molecule. Amplification reactionsinclude, for example, the polymerase chain reaction (PCR), includingquantitative PCR; strand displacement amplification (SDA); transcriptionmediated amplification (TMA); and nucleic acid sequence basedamplification (NASBA). NASBA amplifies RNA. NASBA is described in EP-A-0329 822.

The conventional polymerase chain reaction (PCR) amplification processis well known in the art. Conditions suitable for carrying out apolymerase chain reaction are described in U.S. Pat. Nos. 4,683,195;4,683,202; and 4,965,188. Commercial vendors, such as Perkin Elmer(Norwalk, Conn.), market PCR reagents and publish PCR protocols. A PCRamplification reaction mixture contains reagents necessary to carry outan amplification reaction. Typically, the mixture contains an agent forpolymerization, such as thermostable DNA polymerase; deoxynucleoside 5′triphosphates (dNTP's); and a divalent metal cation in a suitablebuffer.

Either DNA or RNA target sequences can be amplified by the methods ofthe present invention. In the case of PCR amplification of an RNAtarget, such as a viral genomic nucleic acid, the first step is thesynthesis of a DNA copy (cDNA) of the target sequence. The reversetranscription can be carried out as a separate step or, preferably, in acombined reverse transcription-polymerase chain reaction (RT-PCR). TheRT-PCR amplification of RNA is well known in the art and described inU.S. Pat. Nos. 5,322,770 and 5,310,652; Myers and Gelfand, 1991,Biochemistry 30(31):7661-7666; U.S. Pat. No. 5,527,669; Young et al.,1993, J. Clin. Microbiol. 31(4):882-886; and Young et ai., 1995, J.Clin. Microbiol. 33(3):654-657.

Primers are also included in the PCR reaction mixture. A primer is anoligonucleotide which, upon hybridizing to a template nucleic acidmolecule, is capable of acting as a point of synthesis initiation duringan amplification reaction. The template nucleic acid is the initialtarget nucleic acid molecules; and the amplification products generatedfrom these molecules.

The length of the primers of the present invention is not critical.Typically the primer length ranges from about 15 to 55 nucleotides; moretypically from about 20 to 45 nucleotides; and most typically from about25 to 35 nucleotides. Preferably, the primers are constructed to berelatively long (>30 bases) to maximize the number of mismatches thatcan be tolerated between a primer and its template. A primer pair neednot be of the same length. For example, the forward primer may be madeup of twenty-nine nucleotides; while the reverse primer can be made upof twenty-two nucleotides.

The primers can be natural or synthetic. For PCR, the primers arepreferably single-stranded oligodeoxyribonucleotides.

Hybridization refers to the formation of a duplex structure by twosingle-stranded nucleic acids due to complementary base pairing.Hybridization can occur between fully complementary nucleic acid strandsor between “substantially complementary” nucleic acid strands thatcontain minor regions of mismatch, i.e. variants. The degree of mismatchtolerated can be controlled by suitable adjustment of the hybridizationconditions. Conditions under which only fully complementary nucleic acidstrands will hybridize are referred to as “stringent hybridizationconditions” or “sequence-specific hybridization conditions.” Stableduplexes of substantially complementary sequences can be achieved underless stringent hybridization conditions.

The hybridization conditions, i.e. stringency, of the present inventionare set so that the primers can tolerate mismatches between the primersand the template, thereby allowing hybridization to all geneticvariants. For example, the conditions could be set so that hybridizationbetween a primer and a template can occur with up to 20% of the basepairs between the primer and the template mismatched.

Those skilled in the art of nucleic acid technology can determinesuitable hybridization conditions empirically considering a number ofvariables including, for example, the length and base pair concentrationof the oligonucleotides, ionic strength, the incidence of mismatchedbase pairs, and the temperature chosen for oligonucleotide annealing,following the guidance provided by the art (see, e.g., Sambrook et al.,1989, Molecular Cloning—A Laboratory Manual, Cold Spring HarborLaboratory, Cold Spring Harbor, N.Y.; Wetmur, 1991, Critical Reviews inBiochem. and Mol. Biol. 26(3/4):227-259; Ausubel et al. (eds.), 1995,Current Protocols in Molecular Biology, (John Wiley & Sons, Inc., NewYork) at Unit 2.10; and U.S. Pat. No. 5,789,550.)

A detailed description of a cycle of a primer extension chain reactionof the present invention follows. The specific reaction described isPCR. However, other types of primer extension chain reactions can beused in the methods of this invention.

FIG. 10 gives a step-by-step illustration of an amplification reactionof the invention. The target nucleic acid molecule is represented by T.The X's within the target sequence represent sites of potentialvariations.

The target nucleic acid molecule can exist as a single-strandedmolecule, or as part of a double stranded molecule. In the exampleillustrated in FIG. 10, the target nucleic acid molecule is doublestranded. TC represents a nucleic acid molecule which is complementaryto T.

As in conventional PCR, in each cycle of the amplification reaction anydouble-stranded nucleic acid molecules in a sample are renderedsingle-stranded by denaturation. Hybridization then takes place betweenthe primers and the target nucleic acid molecules. FIG. 10( a)illustrates hybridization between a reverse primer (RP) and a targetnucleic acid sequence (T).

As shown in FIG. 10( b), the reverse primers then are extended, usingthe target nucleic acid molecules as templates, to form reverse primeramplification products (RPA). The reverse primer amplification products(RPA) are comprised of the reverse primer (RP) joined to the reverseprimer extension product (RPE). For the purposes of this specification,the reverse primer extension product is the nucleic acid segment whichis added to the reverse primer.

As can be seen from FIG. 10( b), some of the variations (X) contained inthe target sequence do not appear in the RPA. Specifically, the portionof the RPA which is made up of the RP does not contain variations.

As shown in FIG. 10( c), the reverse primer amplification productsformed in step (b) are denatured from their templates.

The forward primers (FP) are hybridized to either: (i) nucleic acidmolecules which are complementary to the target nucleic acid molecules(TC), if present; or (ii) the reverse primer amplification products(RPA). FIG. 10( d) illustrates the former embodiment. Nucleic acidmolecules complementary to the target nucleic acid molecules, would bepresent if the target nucleic acid molecules were part of adouble-stranded molecule.

The forward primers are then extended, using as templates thecomplementary nucleic acid molecules (TC) or using the reverse primeramplification products (RPA). FIG. 10( e) illustrates the formerembodiment.

As shown in FIG. 10( e), the forward primers are extended to formforward primer amplification products (FPA). The forward primeramplification product (FPA) is comprised of the forward primer (FP)joined to the forward primer extension product (FPE). For the purposesof this specification, the forward primer extension product is thenucleic acid segment which is added to the forward primer.

As shown in FIG. 10( e), when compared with the target sequence, some ofthe variations (X) contained in the target sequence do not appear in theFPA. Specifically, the portion of the FPA which is made up of the FPdoes not contain variations.

As shown in FIG. 10( f), the forward primer amplification productsformed in FIG. 10( e) are denatured from their templates.

As shown in FIG. 10( g), the reverse primers hybridize to the FPEportion of the FPA.

As shown in FIG. 10( h), the reverse primers are extended, using the FPportion of the FPA as templates, to form additional reverse primeramplification products (ARPA), wherein a reverse primer joined to anadditional reverse primer extension product (ARPE) constitutes an ARPA.

As shown in FIG. 10( i), the ARPA products are denatured from theirtemplates.

As shown in FIG. 10( j), the forward primers hybridize to the RPEportion of the RPA.

As shown in FIG. 10( k), the forward primers are extended, using the RPportion of the RPAs as templates, to form additional forward primeramplification products, wherein a forward primer joined to an additionalforward primer extension product constitutes an AFPA.

As shown in FIG. 10( l), the AFPA products are denatured from theirtemplates.

Steps (g) to (l) are repeated, using the additional reverse primeramplification products and the additional forward primer amplificationproducts as templates for the reverse and forward primers, a sufficientnumber of times to produce a detectable quantity of additional reverseprimer amplification product and/or of additional forward primeramplification product. Preferably, the steps are repeated using anautomated cycling instrument. A sufficient number of times is at leastabout ten times, preferably at least about twenty times; more preferablyat least about thirty times; and most preferably at least about fortytimes.

The present inventors have discovered advantages when the primershybridize with the amplification products in a certain way, which theinventors refer to as “nose-to-nose.”

As can be seen in FIG. 10( g), the sequence of the forward primeramplification products and the additional forward primer amplificationproducts are such that the nucleotide at the 3′ end of the reverseprimer hybridizes with the nucleotide at the 5′ end of the forwardprimer extension product or of the additional forward primer extensionproduct.

Analogously, as can be seen in FIG. 10( j), the sequence of the reverseprimer amplification products and the additional reverse primeramplification products are such that the nucleotide at the 3′ end of theforward primer hybridizes with the nucleotide at the 5′ end of thereverse primer extension product or of the additional reverse primerextension product.

FIG. 10 illustrates the primer extension chain reaction of only onevariant. As indicated above, all variants of a family of pathogens canbe amplified by the method of the invention.

The additional amplification products are identical, regardless of whichvariant they were generated from. Thus, in the example shown in FIG. 10,the additional reverse primer amplification products have the sequenceof the reverse primer directly joined to the additional reverse primerextension product. The additional reverse primer extension product iscomplementary to the forward primer (the forward primer complement). SeeFIG. 10( h).

Analogously, the additional forward primer amplification products havethe sequence of the forward primer directly joined to the additionalforward primer extension product. The additional forward primerextension product is complementary to the reverse primer (reverse primercomplement). See FIG. 10( k).

Therefore, all of the additional primer amplification products havesequences that are combinations of either the reverse primer and forwardprimer complement, or the reverse primer complement and the forwardprimer. Since the reverse and forward primers all have the samesequences, all of the additional primer amplification products have thesame sequences. In other words, all of the potential variations havebeen eliminated.

In another embodiment, the sequence of the forward primer amplificationproducts and the additional forward primer amplification products aresuch that the nucleotide at the 3′ end of the reverse primer hybridizeswith a nucleotide separated from the nucleotide at the 5′ end of theforward primer extension product or of the additional forward primerextension product by a gap of nucleotides. Analogously, the sequence ofthe reverse primer amplification products and the additional reverseprimer amplification products are such that the nucleotide at the 3′ endof the forward primer hybridizes with a nucleotide separated from thenucleotide at the 5′ end of the reverse primer extension product or ofthe additional reverse primer extension product by a gap of nucleotides.

In both cases, the gap comprises a sequence known to be highlyconserved. Highly conserved regions of the genomes of viruses andbacteria are known. For example, in the published sequence of HCV, shortstretches of nucleic acids in the 5′ non-coding region of the viralgenome are known to be highly conserved between HCV genotypes (Okamotoet al., J. Gen. Virol., 1991,2697-2704; Smith et al., J. Gen. Virol.,1995, 76:1749-1761; Simmonds et al., J. Gen. Virol., 1993, 74:2391-2399).

The gap preferably contains no more than five nucleotides. If the gapcontains two to five nucleotides, one or two of the nucleotides can bemismatched and still hybridize with the probe sequence. If the gapcontains one nucleotide, this nucleotide can be a mismatch. Preferably,there are no mismatches.

Once the amplification reaction has been completed, the presence of theadditional reverse primer amplification products or the additionalforward primer amplification products is detected by methods known inthe art.

Preferably, the method of detection is based on the detection of thenucleic acid sequences of the additional reverse primer amplificationproducts or of the additional forward primer amplification products. Thedetection probe used in such a method comprises a sequence that iscapable of hybridizing with the additional reverse primer amplificationproducts or with the additional forward primer amplification products.Since these amplification products are identical, only one detectionprobe is needed to reliably detect all the amplification products.

Additionally, the identity of the amplification products allows forstringent hybridization conditions to be used during the hybridizationrequired for detection. The use of stringent conditions leads to morereliable results by reducing the possibility of false positives fromcoincidentally similar non-target sequences.

The detection probe can be DNA, RNA, or combinations thereof. Modifiednucleotides may be included, for example peptide nucleic acid (PNA),nitropyrole-based nucleotides, or 2′-O-methylribonucleotides. Thenucleosides of the nucleic acid or modified nucleic acid molecules maybe linked in the usual manner, i.e. through phosphate linkages.Alternatively, the nucleosides may be linked through modified linkages,for example phosphorothioates.

In one embodiment, the probe sequence hybridizes over the junction inthe amplification products. That is, the probe sequence hybridizes to aportion of both the FP sequence and the AFPE sequence of the AFPA; orthe probe sequence hybridizes to a portion of both the RP sequence andthe ARPE sequence of the ARPA.

In this embodiment, the probe sequence is comprised of the nucleotidesequence of a segment of one of the primers and the nucleotide sequenceof a segment which is complementary to the other primer. Morespecifically, the probe sequence comprises either: (i) the nucleotidesequence of a segment of the forward primer and the nucleotide sequenceof a segment which is complementary to the reverse primer; or (ii) thenucleotide sequence of a segment of the reverse primer and thenucleotide sequence of a segment which is complementary to the forwardprimer. The probe sequence can comprise either whole or partialsequences of the primer, and the other primer's complement.

The probe sequence can be made up of equal portions of the nucleotidesequence of one of the primers and the nucleotide sequence of the otherprimer's complement. In such a case, the probe sequence will “hybridizesymmetrically” to the amplification products. (See FIG. 5A(I).)

Preferably, for improved sensitivity, the probe sequence can be designedto “hybridize asymmetrically” to the amplification products. Inparticular, the probe sequence can be made up of unequal portions of thenucleotide sequence of one of the primers and the nucleotide sequence ofthe other primer's complement. (See FIG. 5A(II-IV.) For example, about60% to about 99% of the probe sequence comprises the nucleotide sequenceof one of the primers. The remainder of the probe sequence (e.g., about1% to about 40%) comprises the nucleotide sequence of the complement ofthe other primer. More preferably, the percentage of the probe sequencewhich corresponds to the sequence of one of the primers is from about80% to about 97%.

Where the sequence of the additional amplification products contains asegment of one of the primers directly adjoined to a segment of theother primer's complement, the probe sequence can be designed tohybridize exactly to all, or a portion of, the additional amplificationproducts.

Where the additional amplification products contain an intervening gap,the gap is preferably a known sequence so that the probe sequence can bedesigned to be fully complementary to the gap. However, a probe sequencecan hybridize to additional amplification products which contain acertain number of mismatched residues in the gap, as described above.

Instead of hybridizing over the junction, the probe sequence can alsohybridize exclusively with the segment of the additional amplificationproduct that is complementary to a primer. Accordingly, in thisembodiment, the probe sequence is comprised of either: the nucleotidesequence of a segment of the forward primer, and not the nucleotidesequence of a segment which is complementary to the reverse primer, orthe nucleotide sequence of a segment of the reverse primer, and not thenucleotide sequence of a segment which is complementary to the forwardprimer.

In one embodiment of the primer extension chain reactions of theinvention, equal concentrations of the forward primer and reverse primerare used. In this embodiment, the concentrations are said to besymmetric.

In a preferred embodiment, “asymmetric concentrations” of the forwardand reverse primers are used. In particular, for improved sensitivity,the primer whose nucleotide sequence makes up part of the probe sequenceis provided in a lower concentration in the sample as compared with theother primer. “Asymmetric concentrations” of primers are particularlypreferred if the probe sequences “hybridize asymmetrically” with theadditional amplification products; or hybridize exclusively with thesegment of the additional amplification products that is complementaryto a primer.

For example, if the probe sequence comprises a segment of the nucleotidesequence of the forward primer, then the molar ratio of the forwardprimer to the reverse primer (FP:RP) is about 1:5 to about 1:20.Analogously, if the probe sequence comprises a segment of the nucleotidesequence of the reverse primer, then the molar ratio of the reverseprimer to the forward primer (RP:FP) is about 1:5 to about 1:20, morepreferably from about 1:6 to about 1:15, and most preferably about 1:10.

After the amplification reaction has taken place in the biologicalsample a sufficient number of times, the detection probe is contactedwith the sample. The probe sequence of the detection probe hybridizeswith any additional amplification products that may be present in thesample. If the probe sequence comprises the nucleotide sequence of asegment of the forward primer (exclusively or further comprising thenucleotide sequence of a segment of the reverse primer complement), theprobe sequence will hybridize with the additional reverse primeramplification products. Analogously, if the probe sequence comprises thenucleotide sequence of a segment of the reverse primer (exclusively orfurther comprising and the nucleotide sequence of a segment of theforward primer complement), the probe sequence will hybridize with theadditional forward primer amplification products.

In a preferred embodiment, the detection probe is a self-alteringsignal-generating probe. This probe comprises a first nucleic acidsequence; a second nucleic acid sequence complementary to the firstnucleic acid sequence; and a probe sequence which connects the firstnucleic acid sequence with the second nucleic acid sequence. The firstnucleic acid sequence is attached to a reporter moiety which is capableof generating a detectable signal. The second nucleic acid sequence isattached to an interactive moiety which is capable of altering thesignal generated by the reporter moiety when the reporter moiety and theinteractive moiety are in sufficient proximity to each other. Forexample, when the first and the second nucleic acid sequences arehybridized to one another, known as the “closed conformation,” thereporter moiety is brought into proximity with the interactive moiety.Therefore, the signal is altered. Altering the signal includesdecreasing, i.e. quenching; increasing; or otherwise changing thesignal, such as the intensity or wavelength of the signal. Quenching thesignal includes reducing or eliminating the signal.

The reporter and interactive moieties can be attached at any point onthe detection probe which would allow for the alteration by theinteractive moiety of a signal generated by the reporter moiety fordetection of the additional amplification products. In the preferredembodiment, the reporter moiety and the interactive moiety are attachedat the distal termini of the self-altering signal-generating probe.

In the absence of additional amplification products, the detection probeis in the closed conformation. The reporter and interactive moieties arein proximity to each other. Therefore, the signal is altered.

Upon hybridization of the probe sequence with the additional reverseprimer amplification product or with the additional forward primeramplification product, the first and second nucleic acid sequences ofthe detection probe become denatured. This is known as the “openconformation.”

Upon denaturation, the interactive moiety is no longer in sufficientproximity to the reporter moiety to alter the signal. The differencebetween the altered signal and the unaltered signal is detected. Whenthe interactive moiety quenches the signal, for example, the unalteredsignal is increased; or if the quenching was complete, a signal isgenerated.

The strength of the hybridization formed between the first and secondnucleic acids (i.e., the stem of the probe) can be adjusted by routineexperimentation to achieve proper functioning. For example, the strengthis a function of the length of the nucleotides. The lengths of the firstand second nucleic acid sequences are preferably in the range of about 3to 15, more preferably about 4 to 7 nucleotides. In addition to length,the strength of the hybridization can be reduced by decreasing the G-Ccontent and by inserting destabilizing mismatches in the nucleotides.

The length of the probe sequence is not critical. However, the lengthcannot be so short that effective binding with the additionalamplification products is not achieved. Additionally, the length cannotbe so great that separation of the reporter moiety and the interactivemoiety is not achieved despite the probe sequence being hybridized withthe products. Preferably, the probe sequence comprises from about ten toabout thirty nucleotides; more preferably from about eighteen to abouttwenty-four nucleotides; and most preferably from about nineteen toabout twenty-two nucleotides. The probes can be free in solution, orthey can be tethered to a solid surface.

Any concentration of the detection probe that produces a detectablesignal can be used in the methods. For example, the concentration of thedetection probe can be provided in the sample at about the sameconcentration as one, or both, of the primers.

Preferably, the concentration of the detection probe is greater than theconcentrations of the primers. In this manner, the detection probe isfavored in the competition between the primer, whose nucleic acidsequence is part of the probe sequence, and the detection probe for theadditional amplification products. This increase in the concentration ofthe detection probe is particularly preferred when the probe sequence“hybridizes asymmetrically” to the amplification products, or hybridizesexclusively to the portion of the additional amplification productswhich are complementary to a primer, as described above. For example,the detection probe can be provided at a concentration which is fromabout 1.3 to about 5 times; more preferably from about 1.5 to about 3times; and most preferably about twice as great as the concentration ofthe primer whose nucleic acid sequence is not part of the probesequence.

In a preferred embodiment, the probe sequence is made up of, forexample, at least 65% of the sequence of the forward primer; the forwardprimer is provided in a concentration which is about ten times less thanthe concentration of the reverse primer, and the detection probe isprovided in a concentration which is about twice as great as the reverseprimer.

An unaltered signal generated by the reporter moiety is an indicationthat the target nucleic acid molecule is present in the sample. Thelevel of the detectable unaltered signal generated by the probe isproportional to the quantity of the target nucleic acid molecules in thesample.

The detectable signal of the detection probes can be any kind of signalincluding, for example, a luminescent signal, a color dye signal, or aradioactive signal. In the preferred embodiment, the detectable signalis a luminescent signal. The luminescent signal can be a fluorescentsignal or chemiluminescent signal.

In one embodiment, the reporter and interactive moieties of thisinvention constitute a “FRET” pair. (Selvin, P. R., “FluorescenceResonance Energy Transfer,” Methods in Enzymology 246: 300-335 (1995).)FRET pairs rely on energy transfer for signal generation. The reportermoiety absorbs energy at a first wavelength and emits a second, longerwavelength. The interactive moiety absorbs some or most of the emittedenergy to the degree the interactive moiety's spectrum overlaps theemission spectrum. If the interactive moiety is a quencher, the quencherreleases the energy as heat. If the interactive moiety is a fluorophore,the interactive moiety re-emits at a third, still longer wavelength. Themechanism of FRET-pair interaction requires that the absorption spectrumof the interactive moiety overlaps the emission spectrum of the reportermoiety. The efficiency of FRET interaction is linearly proportional tothat overlap.

In another embodiment, the reporter moiety and interactive moiety are anon-FRET pair. In particular, the interactive moiety need not have anabsorption spectrum that overlaps the emission spectrum of the reportermoiety. That is, the absorption wavelength of the interactive moiety canbe shorter than the reporter's excitation maximum and emissionwavelength. Non-FRET pairs are described in U.S. Pat. No. 6,150,097 andare incorporated herein by reference. The detectable signal in anon-FRET pair can be a change in the absorption spectra, as analternative to a change in luminescence.

Preferably, the reporter moieties of the detection probes used in themethods of this invention are fluorophores. The fluorophore can be axanthene dye, a cyanine dye, a dansyl derivative, EDANS, coumarin, suchas 3-phenyl-7-isocyanatocoumarin, Lucifer yellow, BODIPY, Cy3, Cy5, Cy7,Texas red, erythrosine, naphthylamine, Oregon green, ALEXA fluor dyes,acridines, such as 9-isothiocyanatoacridine and acridine orange,N-(p-(2-benzoxazolyl)phenyl)maleimide, benzoxadiazoles, stilbenes, andpyrenes.

The xanthene dye can be fluorescein or rhodamine. Preferably, thefluorescein is 5-carboxyfluorescein (5-FAM); 6-carboxyfluorescein(6-FAM); 2′,4′,1,4,-tetrachlorofluorescein (TET);2′,4′,5′,7′,1,4-hexachlorofluorescein (HEX); eosin; calcium green;fluorescein isothiocyanate (FITC); or NED. Preferably, the rhodamine dyeis tetramethyl-6-carboxyrhodamine (TAMRA);tetrapropano-6-carboxyrhodamine (ROX);2′,7′dimethoxy-4′,5′-dichloro-6-carboxyrhodamine.(JOE) ortetramethylrhodamine (TMR). Many suitable forms of these compounds arecommercially available with various substituents on their xanthene ringswhich can be used as the site for bonding or as the bondingfunctionality for attachment to an oligonucleotide.

The fluorophore can also be a naphthylamine compound. The naphthylaminecompounds have an amino group in the alpha or beta position. Includedamong such naphthylamino compounds are1-dimethylaminonaphthyl-5-sulfonate, 1-anilino-8-naphthalene sulfonateand 2-p-toluidinyl-6-naphthalene sulfonate.

The fluorophore can also be a combination fluorophore. An example of acombination fluorophore are fluorescein-rhodamine dimers, described, forexample, by Lee et al. (1997), Nucleic Acids Research 25:2816.Fluorophores may be chosen to absorb and emit in the visible spectrum oroutside the visible spectrum, such as in the ultraviolet or infraredranges.

Preferably, the interactive moieties of the detection probes used in themethods of this invention are quenchers. The quencher can be DABCYL,anthroquinone, nitrothiazole, nitroimidazole or malachite green.Variants of DABCYL, such as DABSYL, DABMI or methyl red, are alsosuitable. Also the asymmetric cyanine dye compounds disclosed in U.S.Pat. No. 6,080,868 can be used as the quenching moiety; and areincorporated by reference.

Additionally, fluorophores can also be used as the quenchers. Forexample, fluorophores that do not fluoresce in the detection range whenthe probe is in the open conformation can quench fluorescence when inproximity with certain other fluorophores.

An example of a self-altering signal-generating probe is a molecularbeacon probe. The loop of a molecular beacon probe corresponds to theprobe sequence, as described above. Nucleotide sequences, referred to as“arms,” correspond to the first and second nucleotide sequences, asdescribed above. Molecular beacon probes are described in U.S. Pat. No.5,925,517; PCT application WO95/13399; PCT application WO97/39008; andTyagi and Kramer (1996) Nature Biotechnology 14:303; and areincorporated herein by reference.

Additionally, the molecular beacon probes can be modified in any mannerwhich allows for detection of the amplification products. Modifiedprobes include, for example, the “wavelength-shifting” molecular beaconprobes described in U.S. Pat. No. 6,037,130; and incorporated herein byreference. In particular, these modified probes have the basic molecularbeacon probe structure, namely, a loop; stem duplex; a quencher on oneend; and a reporter moiety, typically a fluorophore, opposite thequencher on the other end. The reporter is referred to as the “harvesterreporter.” The modification of the probe is that the probe includes anextension of several nucleotides past the “harvester reporter.” Theextension terminates in a nucleotide that is linked to an “emitterreporter,” typically another fluorophore. In the presence of the targetnucleic acid molecule, the quencher separates from the reporters. Inthis open conformation the “harvester reporter” absorbs energy from theexcitation source but transfers a significant portion of the energy, insome constructions the great majority of the energy, to the “emitterreporter,” which receives the transferred energy and emits it at itscharacteristic, longer wavelength.

In another embodiment, the detection probe includes a pair ofoligodeoxynucleotides complementary to contiguous regions of theadditional amplification products. (Cardullo et al. (1988), Proc. Nat'l.Acad. Sci. 85: 8790-8794 and Heller et al. EP 00 70685. Oneoligodeoxynucleotide contains the reporter moiety on its 5′ end, and theother oligodeoxynucleotide contains the interactive moiety on its 3′end. When the probe is hybridized to the target sequence, the twomoieties are brought very close to each other. When the sample isstimulated by light of an appropriate frequency, fluorescence resonanceenergy transfer from one moiety to the other occurs, producing ameasurable change in spectral response from the moieties, thus signalingthe presence of targets.

In yet another embodiment, the detection probe includes a pair ofoligodeoxynucleotides. The pair is complementary to one another. Also,one of the pair has the sequence of the target nucleic acid molecule;and the other of the pair has the sequence which is complementary to thetarget nucleic acid molecule. (Morrison and Stols, “SensitiveFluorescence-Based Thermodynamic and Kinetic Measurements of DNAHybridization in Solution,”Biochemistry 32: 309-3104 (1993) and MorrisonEP 0 232 967 A2, claiming priority of U.S. application Ser. No. 817,841,filed Jan. 10, 1986.) Each oligodeoxynucleotide of the probe includes areporter moiety conjugated to its 3′ end and an interactive moietyconjugated to its 5′ end. When the two oligonucleotides of the probe areannealed to each other, the reporter moiety of each is held in closeproximity to the interactive moiety of the other. With the probe in thisconformation, if the reporter is then stimulated by light of anappropriate wavelength, the signal is altered, preferably quenched, bythe interactive moiety. However, when either probe molecule is bound toa target, the altering effect of the complementary oligodeoxynucleotideof the probe is absent. In this conformation a signal is generated. Theoligodeoxynucleotides of the probe are too long to self-quench by FRETwhen in the target-bound conformation.

The signal generated by the detection probe can be detected and measuredby any means known in the art which provides reliable detection andmeasurement.

For example, the ABI-7700 (manufactured by Applied Biosystems, Inc. inFoster City, Calif.) is adapted for measuring signal emission, typicallyfluorescence emissions. The ABI 7700 uses fiber optics connected witheach well in a 96-well amplification reaction tube arrangement. Theinstrument includes a laser for exciting the reporter moieties and iscapable of measuring the signal intensity, typically fluorescencespectra intensity, from each tube with continuous monitoring duringamplification.

The additional amplification products can be quantified by endpoint andreal-time measurements. In an end-point mode, the signal measurement isperformed after the amplification reaction is complete, e.g., after allor substantially all of the cycles of an amplification reaction havebeen completed. In a real-time mode, signal measurement is performedmultiple times during the amplification reaction, e.g., after eachthermocycle of an amplification reaction. The real-time mode ispreferred when a quantitative measure of the initial amount of targetnucleic acid molecule is required, e.g., the copy-number of viral orbacterial nucleic acids present in a sample.

The absolute amount of a target nucleic acid molecule present in a testsample prior to amplification can be determined using a standard curve.For example, a standard curve can be generated from the results obtainedfrom a series of parallel primer extension chain reactions. Theseparallel reactions are performed on a series of standard samples thatcontain a known amount of a nucleic acid molecule which is similar tothe target nucleic acid molecule. A series of about five to about twentystandard samples of different known amounts are used. The parallelextension reactions use the same reaction conditions and reagents asused in the extension reaction of the target nucleic acid molecule.

In each parallel reaction, the increase in signal intensity as comparedwith the baseline signal intensity (delta Rn) is measured at theannealing temperature for each amplification cycle. The baseline valueis the magnitude of the signal detected prior to the formation of theadditional amplification products. Threshold values (Ct) are calculatedfor each reaction. Ct is the amplification cycle number at which thegenerated signal intensity is distinguishable from the baseline signalintensity. The starting quantity of the nucleic acid in each standardsample can be plotted against its corresponding Ct value. This plot isthe standard curve.

In general, the threshold value must be high enough to be statisticallydifferent from the baseline value but below the signal obtained for thesaturation phenomenon associated with amplification reactions.Typically, the threshold value is set at about ten standard deviationsabove the mean baseline signal intensity. (See, for example, Heid, etal. Genome Research 6:986-994 (1996)).

The Ct value for the sample including the target nucleic acid moleculeis also calculated. This Ct value can be plotted against the standardcurve. Using the standard curve, the amount of the target nucleic acidmolecule in the test sample can then be quantified by extrapolation.FIG. 9 illustrates this method of PCR target quantitation (in the caseof HCV RNA) using the “nose-to-nose” PCR primers and reaction conditionsdescribed in the Example below.

Computer software provided with detection instruments, for example theABI 7700, is capable of recording the signal intensity over the courseof an amplification. These recorded values can be used to calculate theincrease in signal intensity on a continuous basis. Although the ABI7700 instrument is typically used to monitor fluorescence, the Ct valuesneed not be determined from fluorescence measurements. Ct values couldbe determined from measurements of a variety of different types ofsignals.

The present invention also relates to kits, multicontainer unitscomprising useful components for practicing the present method. The kitcomprises a set of nose-to-nose primers for the amplification of thevariants of a particular pathogen; and a probe, such as theself-altering signal-emitting probes described above. In some cases, theprobes are fixed to an appropriate support membrane. Other optionalcomponents of the kit include, for example, an agent to catalyze thesynthesis of primer extension products, the substrate nucleosidetriphosphates, the appropriate buffers for amplification and/orhybridization reactions, a nucleic acid reference standard to permitquantitation of template molecules in test samples, and instructions forcarrying out the present method.

EXAMPLES

The examples of the present invention presented below are provided onlyfor illustrative purposes and not to limit the scope of the invention.Numerous embodiments of the invention within the scope of the claimsthat follow the examples will be apparent to those of ordinary skill inthe art from reading the foregoing text and following examples.

Detection of HCV Variants

A comparison was made of three different methods for nucleic acid-baseddetection of eight strains of HCV which are prototypes for the main HCVgenotypes and subtypes. The four detection methods used were: (A.) Thenose-to-nose beacon RT-PCR of the present invention, (B.) Conventionalbeacon RT-PCR, and (C.) The COBAS AMPLICOR HCV MONITOR Test Version 2.0(COBAS HCM-2; Roche Diagnostic Systems Inc, Branchburg, N.J.). The COBASHCM-2, which is an RT-PCR-based assay, was carried out according to themanufacturers' instructions. Conventional beacon RT-PCR and“nose-to-nose” beacon RT-PCR were carried out as follows:

PCR primers were designed to amplify a segment of the 5′ non-codingregion of the HCV genomic RNA. The nucleic acid sequence of this regionof the genome is relatively highly conserved between HCV genotypes andsubtypes.

Conventional primers for beacon PCR were designed to amplify a 101 b.p.segment of DNA corresponding to nucleotides 66 to 166 of the publishedsequence of HCV-H [Inchauspe et al, Proc Natl Acad Sci (USA),88:10292-10296, 1991; Genbank M67463]. The intervening gap between thetwo conventional RT-PCR primers is 61 b.p. in length. The primers are asfollows:

Forward 5′-ACGCAGAAAGCGTCTAGCCA-3′; (SEQ ID NO:1) primer: Reverse5′-GTACTCACCGGTTCCGCAGA-3′. (SEQ ID NO:2) primer:

The primers for “nose-to-nose” RT-PCR of the present invention weredesigned such that there is no intervening nucleotide gap between thetwo primers. The region amplified is a 51 b.p. segment corresponding tonucleotides 83 to 133 of the published sequence of HCV-H. The primersare as follows:

Forward primer: 5′-CCATGGCGTTAGTATGAGTGTCGTGCAGC-3′; (SEQ ID NO:3)Reverse primer: 5′-CCCGGGAGGGGGGGTCCTGGAG-3′. (SEQ ID NO:4)

For both conventional and “nose-to-nose” PCR, the molecular beacon usedfor PCR product detection was5′-FAM-ccgggcTTAGTATGAGTGTCGTGCAGCCTgcccgg-DABCYL-3′ (SEQ ID NO: 5). Thestem nucleic acids are shown in lower case, and the probe loop nucleicacids (corresponding to nucleotides 91 to 113 of the HCV-H sequence) areshown in upper case.

Complementary DNA was reverse transcribed from extracted plasma RNAusing either the conventional reverse primer, or the nose-to-nosereverse primer described above. Each 20 ul reaction contained 2.5 uMreverse primer, 1 unit Mo-MuLV reverse transcriptase (GIBCO BRL, GrandIsland, N.Y.), 1× reverse transcriptase buffer (GIBCO BRL), 5 mMdithiothreitol (DTT), 0.06 units RNasin (Promega, Madison, Wis.), and0.5 mM dNTPs, i.e. dATP, dTTP, dCTP and dGTP (Pharmacia, Piscataway,N.J.). Reactions were incubated at 42° C. for 45 min. The reversetranscriptase was then inactivated by a further incubation at 95° C. for2 min.

For PCR amplification and detection, the products of reversetranscription were incubated in a final volume of 50 μl reaction mixcontaining forward primer (0.1 μM for “nose-to-nose PCR and 1 μM forconventional PCR), 1 μM reverse primer, 1.25 units AmpliTaq Goldpolymerase (Applied Biosystems, Foster City, Calif.), 1× AmpliTaq GoldBuffer II (Applied Biosystems), 2 mM MgCl₂, 0.2 mM dNTPs, and 10 ngmolecular beacon. PCR amplification was performed in the AppliedBiosystems 7700 Sequence Detector using the following cyclingparameters: 95° C. for 10 min (enzyme activation), followed by 44 cycles[95° C., 30 sec (denaturation); 60° C., 1 min (annealing); 72° C.(extension)]. Relative fluorescence of the molecular beacon was measuredat the annealing temperature. Quantitation of HCV template molecules wasachieved by inclusion of an RNA standard curve in each RT-PCRexperiment. The standard curve was constructed using 10, 25, 50, 10²,10³, 10⁴, 10⁵ or 10⁶ molecules synthetic HCV RNA Transcript diluted in 1ug/ml yeast tRNA (Ambion, Austin, Tex.).

Table 1 shows a comparison of the three different methods for detectionof eight strains of HCV. These strains are prototypes for the main HCVgenotypes and subtypes. The nose-to-nose beacon assay of the presentinvention (A) detects all eight genotypes/subtypes, while conventionalbeacon PCR (B) fails to detect Genotypes 4a and 5a.

Results from the COBAS-HCM-2 assay are presented as International Units(I.U.). Although various conversion factors have been suggested(Saldanha et al, Vox Sang, 1999;76(3):149-158; Cuijpers et al,2001;81(1):12-20), the exact relationship between I.U. and HCV RNA copynumber is still under debate, particularly for HCV genotypes other than1a and 1b. Because of this, Roche Diagnostic Systems does not currentlysuggest a conversion factor for results obtained with the COBAS-HCM-2assay. For analytical purposes, it is therefore assumed that I.U. andRNA copy number are equivalent. In comparison with the COBAS-HCM-2assay, the nose-to-nose beacon RT-PCR assay is equivalent to or slightlymore sensitive for Genotypes 1a, 1b, 2b and 6a, but is 1 log (10-fold)more sensitive for Genotype 4a, 0.5 log (3.2-fold) more sensitive forGenotypes 2a and 5a, and 0.3 log (2-fold) more sensitive for Genotype3a. A statistical analysis comparing the relative sensitivity of the twoassays is shown in Table 2.

TABLE 1 A. Nose-to- Nose C. Beacon B. COBAS Test Sample¹ PCRConventional HCM-2 HCV (Log₁₀ RNA Beacon PCR (Log₁₀ Genotype/ VirusStrain Molecules/ (Log₁₀ RNA International Subtype Name ml)Molecules/ml) Units/ml) 1a H strain 5.1 5.0 4.9 1b HC-J4/91 4.7 4.7 4.62a HC-J6 5.1 4.2 4.6 2b HC-J8 4.0 3.7 3.9 3a S52 4.3 3.7 4.0 4a ED43 6.3<2.6 5.3 5a SA13 5.2 <2.6 4.7 6a HK6a 4.8 4.4 4.7 ¹Samples tested wereplasma from chimpanzees which were infected with each of the prototypeHCV strains: H strain [Inchauspe et al, Proc Natl Acad Sci (USA), 88:10292-10296, 1991; Genbank M67463], HC-J4/91 [Okamoto et al, Virology,190: 894-899, 1992; Genbank D10750], HC-J6 [Okamoto et al, J Gen Virol,72: 2697-2704, 1991; Genbank D00944], HC-J8 [Okamoto et al, Virology,188: 331-341, 1992; Genbank D10988], S52 [Bukh et al, Proc Natl Acad Sci(USA) 89: 4942-4946, 1992; Genbank M84837], ED43 [Chamberlain et al, 78:1341-1347, 1997; Genbank Y11604], SA13 [Bukh et al, J Infect Dis, 178:1193-1197; Genbank AF064490], HK6a [Adams et al, Bichem Biophys ResCommun, 234: 393-396, 1997; Genbank Y12083].

TABLE 2 Detection of HCV Genotypes by Nose-to-Nose Beacon PCR and COBASHCM-2 Assays Nose-to-Nose Beacon PCR COBAS HCM-2 HCV (Log₁₀ RNAMolecules/ml) (Log 10 I.U./ml) Genotype x +/− s.d. (n)¹ x +/− s.d. (n)Fold Difference² 1a 5.1 +/− 0.25 (7) 4.9 +/− 0.12 (2) 1.6x 1b 4.7 +/−0.19 (7) 4.6 +/− 0.12 (5) 1.3x 2a 5.1 +/− 0.18 (6) 4.6 +/− 0.22 (6) 3.2x(p = 0.0013) 2b 4.0 +/− 0.22 (7) 3.9 +/− 0.32 (6) 1.3x 3a 4.3 +/− 0.11(7) 4.0 +/− 0.12 (6) 2.0x (p = 0.0032) 4a 6.3 +/− 0.12 (7) 5.3 +/− 0.33(6) 10x (p < 0.0001) 5a 5.2 +/− 0.12 (6) 4.7 +/− 0.26 (6) 3.2x (p =0.0002) 6a 4.8 +/− 0.19 (7) 4.7 +/− 0.90 (2) 1.3x ¹Results are presentedas mean +/− standard deviation of (n) replicate assays. Results from theCOBAS HCM-2 assay are expressed as International Units (I.U.) ²Folddifference in sensitivity of the two assays is calculated as thearithmetic ratio of values obtained by Nose-to-Nose Beacon PCR to thoseobtained by the Roche Monitor Assay. Two-tailed P values were calculatedusing GraphPad InStat Software.

Screening of Plasma Samples from Individuals Infected with Diverse HCVGenotypes

The “nose-to-nose” PCR of the present invention was used to screen asubset of patient plasma samples from the ICBS HCV Master Panel. Thispanel, which is being expanded continually, is compiled by the Centersfor Disease Control (CDC) in collaboration with the InternationalConsortium for Blood Safety (ICBS). The panel consists of plasma samplescollected from diverse geographic regions. All samples are screened forHCV antibody and are subjected to genotype analysis in two independenttesting laboratories at the CDC and at Visible Genetics Inc. (VGI).

A total of 192 specimens, comprising plasma samples collected in Egypt,Vietnam and Indonesia were provided by the CDC. Of these, 134 werelisted as being unequivocally positive for HCV RNA on the basis ofPCR-genotyping data obtained by CDC, VGI or both. Five samples werelisted as having equivocal or conflicting PCR-genotype data. Fifty-threesamples were listed as not genotypeable (i.e. negative for HCV RNA).

Total RNA was extracted from 70 μl freshly thawed plasma using a roboticextraction procedure in which RNA is bound and eluted from PVDFmembranes in 96-well plate format (Lee and Prince, 2001, Transfusion;41:483-487). Total RNA was obtained in a volume of 50 μl nuclease-freewater. Ten microliters of this (equivalent to 14 μl plasma) were thensubjected to reverse transcription and PCR using the nose-to-noseprimers (SEQ ID NO: 3 and SEQ ID NO: 4) and molecular beacon (SEQ ID NO:5) described above.

Table 2 shows the results of RT-PCR for the 134 unequivocallyHCV-positive samples present in the panel. “Nose-to-nose” PCRsuccessfully detected the vast majority of HCV isolates from allgenotypes. Of the 53 samples which were not positive for HCV RNA ingenotype assays, only one sample gave a weakly positive PCR signal(10^(3.1) RNA molecules per ml).

Samples with a virus burden less than ˜700 copies/ml (9.9 copies per 14ul plasma) would not be detected using the combination of roboticextraction and “nose-to-nose” RT-PCR describe above. The results shownin Table 2 clearly demonstrate that the present invention permits thedetection of diverse HCV genotypes with a single set of “nose-to-nose”primers and molecular beacon.

TABLE 2 Range Total Detected/Total (Log₁₀ RNA Molecules/ml GenotypeTested Plasma) (%) 1a 22/23 3.13-6.93 95.7 1b 19/20 3.18-7.13 95.0 1c3/3 5.84-6.72 100 2a 3/3 3.85-6.85 100 2e 1/1 6.69 100 3a 3/3 4.36-6.8 100 3b 1/1 4.93 100 4a 43/43 3.78-7.0  100 4d 9/9 5.08-6.56 100 4l 1/16.25 100 6a 8/8 3.28-6.37 100 10a (3) 5/6 4.22-7.23 83.3 Ambiguous***12/13 4.11-6.85 92.3 TOTAL 130/134 97.0 ***Samples for which genotypinganalysis indicated mixed infection or as yet indeterminateclassification have been listed separately.

Comparison of Nose-to-Nose PCR and Conventional PCR for Detection ofHIV-1 Group M Subtype B Variants

FIG. 6 a shows an alignment of proviral DNA sequences corresponding tothe V3 region and flanking sequences of four different HIV variants, allof Group M (Major) Subtype B (HIV/RT-1, HIV/RT10, HIV-38-1 andHIV/38/3). The V3 region is the most highly variable segment of the HIVgenome. A molecular beacon was designed with a probe-loop structureexactly identical to variant HIV/RT-1 (nucleotides 76-97 on the V3sequence shown). This probe sequence possesses 1, 3, or 4 mismatcheswith variants HIV/RT-10, HIV/38-1 and HIV/38-3 respectively (FIG. 6 a).

PCR primers for “nose-to-nose” PCR were designed as follows. The forwardprimer (5′-acaatacaagaaaaaggataactatgggac-3′) (SEQ ID NO: 6) correspondsto nucleotides 65-94 of the sequence of HIV/RT-1 shown in FIG. 6 a. Theforward primer is known as NBF. The reverse primer(5′tttctcctgttgtataaagtactctccccg-3′) (SEQ ID NO: 7) corresponds tonucleotides 95-124 of the same sequence. The reverse primer is known asNBR.

Primers for conventional PCR were designed to generate a 177 b.p. PCRproduct as follows. The forward primer (5 ′taatagtacagctgaatgaatctg-3′)(SEQ ID NO: 8) corresponds to nucleotides 14-37 of the sequence ofHIV/RT-1 shown in FIG. 6 a. The reverse primer (5′gttttaaagtgttattccatgc-3′) (SEQ ID NO: 9) corresponds to nucleotides168-190 of the same sequence.

FIG. 7 shows the results of an experiment to compare the ability ofconventional beacon PCR with nose-to-nose PCR for detection of each ofthe 4 HIV variants shown in FIG. 6 a. PCR reactions contained 10⁶template molecules of HIV/RT-1, HIV/RT-10, HIV/38-1 or HIV/38-3, themolecular beacon shown in FIG. 6 b, and either the conventional ornose-to-nose primers described above. Control PCR reaction containedeither no template or 150 ng human genomic DNA. Amplification wasperformed in the Perkin Elmer 7700 using the following cyclingparameters: 95° C. for 10 min, followed by 40 cycles of 95° C. for 30sec (denaturation), 50° C. for 1 min (annealing) and 72° C. for 30 sec(extension). Fluorescence of the molecular beacon was measured at the50° C. annealing temperature. Fluorescence was then plotted graphicallyagainst PCR cycle number. Efficiency of PCR amplification/detection isdetermined by the “threshold cycle” i.e. the lowest numbered PCR cyclerequired to generate a positive fluorescent signal.

As shown in FIG. 7 a, the conventional beacon PCR technique was capableof detecting both HIV/RT-1 (exact match to the beacon) and HIV/RT-10(one mismatch), with an equivalent threshold cycle (cycle 23) althoughthe peak level of fluorescence obtained in the latter case was ˜2 foldlower than that for the exact-match template. The conventional beaconPCR technique failed to detect either HIV/38-1 (3 mismatches) orHIV/38-3 (4 mismatches), despite the fact that PCR product was generatedfrom all 4 variants, as shown by gel analysis (FIG. 8).

By contrast, the nose-to-nose PCR technique was capable of detecting all4 HIV variants (0, 1, 3 or 4 mismatches) with comparable threshold cycle(FIG. 7 b). Importantly, no signal was detected in reaction tubescontaining either no template, or 150 ng human genomic DNA.

Detection of Different Subtypes of HIV-1 Group M

PCR primers were designed to amplify a segment of the gag gene of theHIV-1 genomic RNA, which is relatively well conserved between thedifferent Subtypes of HIV-1 Group M. Despite this relative conservation,individual HIV-1 Subtypes show up 20% nucleotide sequence diversitywithin this region of the genome (Roberton et al, 1999 in: HumanRetroviruses and AIDS 1999, pp 492-505, Editors Kuiken et al, Los AlamosNational Laboratory, Los Alamos, N. Mex.).

Conventional primers for beacon PCR were designed to amplify a 94 b.p.segment of RNA corresponding to nucleotides 1478 to 1571 of thepublished sequence of the Subtype B HIV-1 isolate HXB2 [Ratner et al,1985, Nature, 313(6000):277-284; Genbank K03455]. The intervening gapbetween the two conventional RT-PCR primers is 53 b.p. The primers areas follows:

Forward primer: 5′-AACCAAGGGGAAGTGACATA-3′ (SEQ ID NO: 10);

Reverse primer: 5′-ATTTCTCCTACTGGGATAGGT-3′ (SEQ ID NO: 11).

The primers for “nose-to-nose” RT-PCR of the present invention weredesigned to amply a 57 b.p. segment corresponding to nucleotides 1502 to1558 of the published sequence of HIV-1 HXB2. There is no interveninggap between the two primers. The primers are as follows

Forward primer: 5′-GAACTACTAGTACCCTTCAGGAACAAATAG-3′; (SEQ ID NO:12)Reverse primer: 5′-GGATAGGTGGATTATTTGTCATCCATC-3′. (SEQ ID NO:13)

For both conventional and “nose-to-nose” PCR, the molecular beacon usedfor PCR product detection was5′-FAM-cgcctTACCCTTCAGGAACAAATAGaggcg-DABCYL-3′ (SEQ ID NO: 14). Thestem nucleic acids are shown in lower case, and the probe loop nucleicacids (corresponding to nucleotides 1512 to 1530 of the HIV-1 HXB2sequence) are shown in upper case.

Virus isolates from HIV-1 Subtypes A, B, C, D, F and G were obtained ascell-free culture supernatants from the AIDS Research and ReferenceReagent Program, Division of AIDS, NIAID, NIH. RNA was extracted from140 ul freshly thawed culture supernatant Complementary DNA was reversetranscribed from extracted RNA using either the conventional reverseprimer, or the nose-to-nose reverse primer described above. Reactionconditions for both cDNA synthesis and PCR amplification wereessentially the same as those described above for HCV. All assays werecarried out in triplicate. Quantitation of HIV template molecules wasachieved by inclusion of an RNA standard curve in each RT-PCRexperiment. The standard curve was constructed using 1, 10, 10², 10³,10⁴, 10⁵ or 10⁶ molecules HIV-1 RNA diluted in 1 μg/ml yeast tRNA(Ambion, Austin, Tex.).

Table 3 shows a comparison of conventional RT-PCR and “nose-to-nose”RT-PCR for detection of HIV-1 Subtypes. The “nose-to-nose” assay of thepresent invention (A.) detects all 6 HIV-1 Subtypes tested, while theconventional assay fails to detect Subtypes A, D and G.

TABLE 3 Log₁₀ RNA molecules per ml of culture supernatant detected by:Test Sample¹ Conventional “Nose-to-Nose” HIV-1 Subtype Virus Strain NameBeacon RT-PCR Beacon RT-PCR A 92UG029² <3.9  9.7 +/− 0.05 B 92BR014² 9.3+/− 0.3 9.3 +/− 0.1 C 92BR025² 9.4 +/− 0.2 9.2 +/− 0.3 D 94UG114² <3.910.2 +/− 0.06 F 93BR020² 4.8 +/− 0.6 5.6 +/− 0.2 G Jv1083³ <3.9 9.8 +/−0.2 No Template — <3.9 <3.9 ¹Test samples were virus isolates obtainedas cell-free culture supernatants from the AIDS Research and ReferenceReagent Program, Division of AIDS, NIAID,NIH. ²Isolates contributed byThe UNAIDS Network for HIV Isolation and Characterization, and theDAIDS, NIAID. ³Abimiku et al, 1994, AIDS Res Hum Retroviruses, 10(11):1581-1583.

Adaptation of the Method for Simultaneous Detection of Both HIV-1 GroupM and HIV-1 Group O Variants

Virus isolates from HIV-1 Group 0 (Outlier) show marked sequencevariation from members of HIV-1 Group M (Major). Although Group Oviruses are mainly prevalent in parts of Africa, their frequency amongsamples collected by blood banks outside Africa appears to be increasing(Jaffe and Schochetman, 1998, Infect Dis Clin North Am; 12(1):3946;Couturier et al, 2000, AIDS; 14(3):289-296; Fed Regist, Sep. 23,1997;62(184):49695). The present invention permits detection of membersof both Group M and Group O using a single set of “nose-to-nose” primersand molecular beacon.

The primers for “nose-to-nose” RT-PCR of the present invention weredesigned to amplify a 64 b.p. segment of the pol gene of the HIV-1genomic RNA, corresponding to nucleotides 4750 to 4813 of the publishedsequence of HIV-1 HXB2. There is no intervening gap between the twoprimers. The primers are as follows

Forward primer: 5′-CAGCAGTACAAATGGCAGTATTCATTCACAATTT-3′; (SEQ ID NO:15)Reverse primer: 5′-CTGTATCCCCCAATCCCCCCTTTTCTTTTTA-3′. (SEQ ID NO:16)

The molecular beacon used for PCR product detection was5′-FAM-cgcacgGCAGTATTCATTCACCAATTTTcgtgcg-DABCYL-3′ (SEQ ID NO: 17). Thestem nucleic acids are shown in lower case, and the probe loop nucleicacids are shown in upper case.

The new primers and beacon were then tested for their ability to amplifyand detect virus isolates from HIV-1 Group M (Subtypes A, B, C, D, F andG) and Group 0, which were obtained as cell-free culture supernatantsfrom the AIDS Research and Reference Reagent Program, Division of AIDS,NIAID/NIH. Prior to RNA extraction, all cell supernatants were diluted1000-fold in phosphate buffered saline (PBS). RNA extraction wasperformed on the diluted supernatant essentially as described above,except that following isolation, all RNA samples were treated withRNase-free DNase (Ambion, Austin, Tex.) to ensure removal ofcontaminating proviral DNA. Complementary DNA was reverse transcribedfrom extracted RNA using the nose-to-nose reverse primer (SEQ ID NO: 16)described above. Reaction conditions for both cDNA synthesis and PCRamplification were essentially the same as those described above.Quantitation of HIV-1 template molecules was achieved by inclusion of anRNA standard curve in each RT-PCR experiment.

Table 4 shows the results of RT-PCR using the pol region “nose-to-nose”primers of the present invention, and a comparison with the COBASAMPLICOR HIV-1 Monitor Assay Version 1.0 (Roche Diagnostics, Branchburg,N.J.). The “nose-to-nose” RT-PCR assay was capable of detecting allGroup M and Group O isolates tested, with sensitivity equal to (Group M,Subtypes B and C) or greater than (Group M, Subtypes A, D and F) theCOBAS AMPLICOR HIV-1 Monitor Assay (1.0). The latter assay failed todetect either of the Group O virus isolates tested, and also failed todetect Group M Subtype G. These data are in agreement with a recentreport that neither the COBAS AMPLICOR HIV-1 Monitor Assay (1.0) nor itsimproved version (1.5) are capable of detecting group 0 viruses (Yang etal, Transfusion, 2001;41:643-651). In contrast, the present inventionpermits detection of all virus isolates with a single set of“nose-to-nose” primers and molecular beacon.

TABLE 4 Log₁₀ RNA molecules per ml of diluted culture Test Sample¹Supernatant detected by: Virus COBAS Amplicor HIV-1 HIV-1 Strain²“Nose-to-Nose” Monitor Subtype Name Beacon RT-PCR Version 1.0 A 92UG0295.1 +/− 0.17 3.5 +/− 0.10 B 92BR014 5.4 +/− 0.62 5.2 +/− 0.03 C 92BR0255.6 +/− 0.04 5.5 +/− 0.04 D 94UG114 5.9 +/− 0.46 5.2 +/− 0.05 F 93BR0205.7 +/− 0.80 3.7 +/− 0.09 G Jv1083 7.3 +/− 0.08 Negative O L20571 5.4+/− 0.66 Negative O Y14496 6.0 +/− 0.38 Negative Human DNA (100 ng)³<3.0 Not Tested Human RNA (100 ng)³ <3.0 Not Tested ¹Prior to RNAextraction, all cell free supernatants were diluted 1000 fold in eitherPBS (for “nose-to-nose” RT-PCR) or normal human plasma (for COBASAmplicor HIV-1 Monitor Version 1.0). ²Virus isolates are as described inTable 3; isolate L20571, Gurtler LG et al, 1994, J Virol, 68: 1581;isolate Y14496, Loussert-Ajaka I, et al. J Virol 69: 5640, 1995.³“Nose-to-nose” PCR or RT-PCR was also performed on 100 ng of human DNAor RNA to verify that the observed signals were due to virusamplification, and not amplification of contaminating human nucleicacids.

1. In a primer extension chain reaction method for determining thepresence of a target nucleic acid molecule in a sample, the methodcomprising: (a) hybridizing a reverse primer to the target nucleic acidmolecule under conditions suitable for carrying out a primer extensionchain reaction; (b) extending the reverse primer using the targetnucleic acid molecule as a template to form a reverse primer extensionproduct, wherein the reverse primer joined to the reverse primerextension product constitutes a reverse primer amplification product;(c) denaturing the reverse primer amplification product from itstemplate; (d) hybridizing a forward primer to: (i) a nucleic acidmolecule which is complementary to the target nucleic acid molecule, ifpresent; or (ii) the reverse primer amplification product; (e) extendingthe forward primer using the complementary target nucleic acid molecule,if present, or the reverse primer amplification product, as a template,wherein the forward primer joined to the forward primer extensionproduct constitutes a forward primer amplification product; (f)denaturing the forward primer amplification product from its template;(g) hybridizing the reverse primer to the forward primer amplificationproduct; (h) extending the reverse primer using the forward primeramplification product as a template to form an additional reverse primerextension product, wherein the reverse primer joined to the additionalreverse primer extension product constitutes an additional reverseprimer amplification product; (i) denaturing the additional reverseprimer amplification product from its template; (j) hybridizing theforward primer to the reverse primer amplification product; (k)extending the forward primer using the reverse primer amplificationproduct as a template to form an additional forward primer extensionproduct, wherein the forward primer joined to the additional forwardprimer extension product constitutes an additional forward primeramplification product; (l) denaturing the additional forward primeramplification product from its template; (m) repeating steps (g) through(l), using the additional reverse primer amplification product and theadditional forward primer amplification product as templates for theforward primer and the reverse primer, respectively, a sufficient numberof times to produce a detectable quantity of additional reverse primeramplification product or of additional forward primer amplificationproduct; and (n) detecting the presence of the additional reverse primeramplification product or the additional forward primer amplificationproduct; the improvement wherein the nucleotide at the 3′ end of thereverse primer hybridizes with: (i) the nucleotide at the 5′ end of theforward primer extension product or of the additional forward primerextension product; or (ii) a nucleotide separated from the nucleotide atthe 5′ end of the forward primer extension product or of the additionalforward primer extension product by a gap of nucleotides, wherein thegap comprises a sequence known to be highly conserved; and wherein thenucleotide at the 3′ end of the forward primer hybridizes with: (i) thenucleotide at the 5′ end of the reverse primer extension product or ofthe additional reverse primer extension product; or (ii) a nucleotideseparated from the nucleotide at the 5′ end of the reverse primerextension product or of the additional reverse primer extension productby a gap of nucleotides, wherein the gap comprises a sequence known tobe highly conserved.
 2. The method according to claim 1 wherein thetarget nucleic acid molecules are known to have variant sequences. 3.The method according to claim 1 wherein the primer extension chainreaction is a polymerase chain reaction (PCR).
 4. The method accordingto claim 1 wherein the target nucleic acid molecule is a virus.
 5. Themethod according to claim 4 wherein the virus is human immunodeficiencyvirus (HIV).
 6. The method according to claim 4 wherein the virus ishepatitis C virus (HCV) or hepatitis B virus (HBV).
 7. The methodaccording to claim 4 wherein the gap comprises a highly conserved regionof the genome of the virus.
 8. The method according to claim 1 whereinthe gap comprises from about one to about five nucleotides.
 9. Themethod according to claim 8 wherein the gap comprises about twonucleotides.
 10. The method according to claim 3 wherein the nucleicacid molecule which is complementary to the target nucleic acid moleculeof step (d)(i) is provided separately as the cDNA of the target nucleicacid molecule.
 11. The method according to claim 1 wherein detecting thepresence of the additional reverse primer amplification product or theadditional forward primer amplification product comprises: (A) providinga self-altering signal-generating probe, wherein the probe comprises:(i) a first nucleic acid sequence attached to a reporter moiety capableof generating a detectable signal; (ii) a second nucleic acid sequencethat: (a) is complementary to the first nucleic acid sequence, and (b)is attached to an interactive moiety capable of altering the signal ofthe reporter moiety when the first nucleic acid sequence and the secondnucleic acid sequence are hybridized to each other; and (iii) a probesequence which connects the first nucleic acid sequence and the secondnucleic acid sequence; wherein the probe sequence comprises either: (a)the nucleotide sequence of a segment of the forward primer; or (b) thenucleotide sequence of a segment of the reverse primer; and (B)contacting the amplification products with the probe; wherein when theprobe sequence of the probe hybridizes with the additional reverseprimer amplification product or with the additional forward primeramplification product, the first and second nucleic acid sequencesbecome denatured, thereby generating a signal by the reporter moiety;and wherein the signal generated by the reporter moiety indicates thepresence of the target molecule.
 12. The method according to claim 11wherein the probe sequence comprises either: (a) the nucleotide sequenceof a segment of the forward primer, and not the nucleotide sequence of asegment which is complementary to the reverse primer; or (b) thenucleotide sequence of a segment of the reverse primer, and not thenucleotide sequence of a segment which is complementary to the forwardprimer.
 13. The method according to claim 11 wherein the probe sequencecomprises either: (a) the nucleotide sequence of a segment of theforward primer and the nucleotide sequence of a segment which iscomplementary to the reverse primer; or (b) the nucleotide sequence of asegment of the reverse primer and the nucleotide sequence of a segmentwhich is complementary to the forward primer.
 14. The method accordingto claim 11 wherein the level of the detectable signal generated by theprobe is proportional to the quantity of the target nucleic acidmolecule in the sample.
 15. The method according to claim 13 whereinabout sixty to about ninety-five percent of the probe sequence compriseseither: (i)the nucleotide sequence of a segment of the forward primer;or (ii)the nucleotide sequence of a segment of the reverse primer. 16.The method according to claim 11 wherein: if the probe sequencecomprises the nucleotide sequence of a segment of the reverse primer,the molar ratio of the reverse primer to the forward primer is in therange from about 1:5 to about 1:20; or if the probe sequence comprisesthe nucleotide sequence of a segment of the forward primer, the molarratio of the forward primer to the reverse primer is in the range fromabout 1:5 to about 1:20.
 17. The method according to claim 11 whereinthe probe sequence comprises from about ten to about thirty nucleotideresidues.
 18. The method according to claim 17 wherein the probesequence comprises from about eighteen to about twenty-four nucleotideresidues.
 19. The method according to claim 11 wherein the detectablesignal is a luminescent signal.
 20. The method according to claim 19wherein the luminescent signal is a fluorescent signal.
 21. The methodaccording to claim 19 wherein the luminescent signal is chemiluminescentsignal.
 22. The method of claim 11 wherein the reporter moiety isattached at the 5′ terminus or 3′ terminus of the self-alteringsignal-generating probe.
 23. The method of claim 11 wherein theinteractive moiety is attached at the 5′ terminus or 3′ terminus of theself-altering signal-generating probe.
 24. The method according to claim11 wherein the reporter moiety is a fluorophore.
 25. The methodaccording to claim 24 wherein the fluorophore is a xanthene dye, acyanine dye, a dansyl derivative, EDANS, coumarin, Lucifer yellow,BODIPY, Cy3, Cy5, Cy7, Texas red, erythrosine, naphthylamine, Oregongreen, or combinations thereof.
 26. The method according to claim 25wherein the xanthene dye is a fluorescein or a rhodamine.
 27. The methodaccording to claim 26 wherein the fluorescein is selected from the groupconsisting of 5-carboxyfluorescein (5-FAM); 6-carboxyfluorescein(6-FAM); 2′,4′,1,4,-tetrachlorofluorescein (TET);2′,4′,5′,7′,1,4-hexachlorofluorescein (HEX); eosin; calcium green; andNED.
 28. The method according to claim 26 wherein the rhodamine isselected from the group consisting of tetramethyl-6-carboxyrhodamine(TAMRA); tetrapropano-6-carboxyrhodamine (ROX); 2′,7′dimethoxy-4′,5-dichloro-6-carboxyrhodamine (JOE); andtetramethylrhodamine.
 29. The method according to claim 11 wherein theinteractive moiety is a quencher.
 30. The method according to claim 29wherein the quencher is DABCYL, anthroquinone, nitrothiazole,nitroimidazole or malachite green.
 31. The method according to claim 30wherein the DABCYL is DABSYL, DABMI or methyl red.
 32. The methodaccording to claim 11 wherein the interactive moiety is a fluorophore.33. The method of claim 1 wherein the amplification products aremeasured and quantitated by end-point analysis.
 34. The method of claim1 wherein the amplification products are measured and quantitated byreal-time analysis.
 35. The method of claim 1 wherein the amplificationproducts are measured using a standard curve derived from a series ofthreshold cycle measurements.